Ensign Peak Advisors
RLAY icon

Ensign Peak Advisors’s Relay Therapeutics RLAY Stock Holding History

Ensign Peak Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-64,900
Closed -$170K – 1716
2025
Q1 		$170K Hold
64,900
– – ﹤0.01% 1678
2024
Q4 		$267K Buy
64,900
+9,450
+17% +$51.4K ﹤0.01% 1686
2024
Q3 		$393K Hold
55,450
– – ﹤0.01% 1657
2024
Q2 		$362K Buy
55,450
+10,850
+24% +$74.1K ﹤0.01% 1666
2024
Q1 		$370K Sell
44,600
-2,250
-5% -$21.9K ﹤0.01% 1672
2023
Q4 		$516K Buy
46,850
+7,950
+20% +$67.1K ﹤0.01% 1654
2023
Q3 		$327K Hold
38,900
– – ﹤0.01% 1675
2023
Q2 		$489K Hold
38,900
– – ﹤0.01% 1640
2023
Q1 		$641K Buy
+38,900
New +$698K ﹤0.01% 1553
2022
Q4 		– Sell
-16,870
Closed -$377K – 2136
2022
Q3 		$377K Buy
16,870
+12,210
+262% +$268K ﹤0.01% 1603
2022
Q2 		$78K Hold
4,660
– – ﹤0.01% 2012
2022
Q1 		$139K Hold
4,660
– – ﹤0.01% 1963
2021
Q4 		$143K Buy
+4,660
New +$147K ﹤0.01% 2000

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ensign Peak Advisors's RLAY Position: Q2 2025 in Review

Ensign Peak Advisors sold out of Relay Therapeutics (RLAY) in Q2 2025, closing a stake of 64,900 shares — an estimated $170K sold.

Ensign Peak Advisors first reported a position in RLAY in Q4 2021 and held it in 13 quarters. The position peaked at $641K in Q1 2023. 208 funds tracked by Wall St. Rank hold RLAY as of Q2 2025.

  • Ensign Peak Advisors reported no remaining Relay Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 64,900 Relay Therapeutics shares in Q2 2025, an estimated $170K.
  • Ensign Peak Advisors first reported a position in Relay Therapeutics in Q4 2021 and held it in 13 quarters.
  • Ensign Peak Advisors's Relay Therapeutics position peaked at $641K in Q1 2023.
  • 208 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2025.

Based on Ensign Peak Advisors's 13F filing for Q2 2025, filed 12 Aug 2025.